Form 8-K AIM ImmunoTech Inc. To: July 14
Enter Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
SECURITY AND EXCHANGE COMMISSION
Washington, DC 20549
REPORT IN PROGRESS
In accordance with Article 13 or 15 (d) of the
1934 Stock Exchange Act
Report date (Date of first reported event)
July 14, 2021
AIM IMMUNOTECH INC.
(Exact name of the declarant as specified in his charter)
|Delaware||001 – 27072||52-0845822|
|(State or other jurisdiction||(Commission||(IRS employer|
|of constitution)||File number)||ID number.)|
|2117 SW Highway 484, Ocala FL||34473|
|(Address of the main executive offices)||(Postal code)|
Cardholder’s phone number, including area code: (352) 448-7797
AIM ImmunoTech Inc.
(Old name or old address, if changed since the last report)
Check the appropriate box below if the filing of Form 8-K is intended to simultaneously satisfy the filer’s filing obligation under any of the following provisions (see General Instruction A.2. Below ):
|[Â Â ]||Written communications in accordance with Rule 425 of the Securities Act (17 CFR 230.425)|
|[Â Â ]||Solicitation of documents in accordance with Rule 14a-12 of the Exchange Act (17 CFR 240.14a-12)|
|[Â Â ]||Pre-launch communications in accordance with Rule 14d-2 (b) of the Exchange Act (17 CFR 240.14d-2 (b))|
|[Â Â ]||Pre-launch communications pursuant to Exchange Act Rule 13e-4 (c) (17 CFR 240.13e-4 (c))|
Indicate with a check mark whether the declarant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Â§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Â§240.12b – 2 of this chapter).
Emerging, growing company [Â Â ]
If it is an emerging growth company, indicate with a check mark whether the declarant has chosen not to use the extended transition period to comply with the new financial or revised accounting standards provided for under Article 13 (a) of the Exchange Act. [Â Â ]
Securities registered in accordance with Article 12 (b) of the Law:
|Title of each class||Trade symbol||Name of each exchange on which registered|
|Common shares, par value $ 0.001 per share||GOAL||American NYSE|
|Article 7.01.||FD Regulation Disclosure.|
On July 14, 2021, AIM ImmunoTech Inc. (the âCompanyâ) posted a presentation of the Company in the âEvents and Presentationsâ subsection of the âInvestor Relationsâ tab on the Company’s website at the address https://AIMImmuno.com. The presentation will be discussed during the Investor Update webcast scheduled for 11:00 a.m. Eastern Time on Wednesday, July 14, 2021.
The webcast can be viewed at https://www.webcaster4.com/Webcast / Page / 2605/41875 or on the Company’s website at https://aimimmuno.com/events-presentations/. For those who are unable to attend at that time, a replay of the webcast will be available until Thursday, July 14, 2022 on the Company’s website.
The information in this article, including Exhibit 99.1, is “provided” and will not be considered “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the responsibilities of this section. It may not be incorporated by reference in another filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, if and to the extent that such subsequent filing specifically refers to the information contained herein as being incorporated by reference in such deposit.
After lengthy discussions with Roswell Park, AIM determined that it was not in the best interests of its shareholders to waive the âthird party beneficiaryâ rights to any pre-existing intellectual property of AIM without appropriate compensation and license terms. This business decision has created a deadlock, which means AIM currently has no plans to move forward with some trials planned – but not yet launched – at Roswell Park. Additionally, unlike pancreatic cancer and advanced relapsing ovarian cancer, these earlier planned studies from Roswell Park are not on the Company’s short-term critical path for future new drug applications and will only become a priority. that once the Company has achieved its objectives related to pancreatic cancer advanced relapsing ovarian cancer. For more information, please see the attached Company Presentation as Exhibit 99.1.
This current report on Form 8-K, including Exhibit 99.1, contains forward-looking statements that involve a number of risks and uncertainties. Among other things, for these statements, the Company claims safe harbor protection for the forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. All forward-looking statements set forth herein speak only as of the date of these statements. present. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. The Company is in various stages of researching the efficacy of Ampligen in the treatment of several types of viral diseases, cancers and immunodeficiency disorders and the presentation provided as Exhibit 99.1 outlines the planned future activities of the society. These planned activities are subject to change for a number of reasons. Significant additional tests and trials will be needed to determine whether Ampligen will be effective in treating these conditions. Results obtained in animal models do not necessarily predict results in humans. Human clinical trials will be needed to prove whether Ampligen will work in humans or not. No assurance can be given as to whether ongoing or planned clinical trials will be successful or yield favorable data and trials are subject to many factors including lack of regulatory approval (s) , lack of study drug or change of priorities in institutions sponsoring further trials. In addition, the launch of planned clinical trials may not happen due to many factors including lack of regulatory approval (s) or lack of study drug. Even if these clinical trials are initiated, the Company cannot guarantee that the clinical studies will be successful or provide useful data or require additional funding. Some of the world’s largest pharmaceutical companies and medical institutions are rushing to find treatment for COVID-19. Even if Ampligen is found to be effective in combating the virus, no assurance can be given that our actions to prove this will be prioritized or that other treatment which ultimately proves capable will not render our efforts ultimately unproductive. The Society recognizes that all cancer centers, like all medical institutions, must make the pandemic their priority. Therefore, there is a potential for delay in recruiting for clinical trials and reporting ongoing studies. No assurance can be given that future studies will not produce results different from those reported in the studies referenced in the presentation. In addition, many countries, including Argentina, are facing outbreaks of COVID-19 and have made it their primary focus. The Company believes this could delay the commercialization of Ampligen in Argentina until COVID-19 is better under control. The Company cannot guarantee that its potential foreign operations will not be adversely affected by these risks.
Article 9.01. Financial statements and supporting documents.
In accordance with the requirements of the Securities Exchange Act of 1934, the declarant has duly caused this report to be signed on his behalf by the undersigned, duly authorized.
|AIM IMMUNOTECH INC.|
|July 14, 2021||Through:||/ s / Thomas K. Equels|
|Thomas K. Equels, CEO|